Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron‐specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6–8 weeks and the...

Full description

Saved in:
Bibliographic Details
Published in:EMBO reports 2006-09, Vol.7 (9), p.940-946
Main Authors: Radde, Rebecca, Bolmont, Tristan, Kaeser, Stephan A, Coomaraswamy, Janaky, Lindau, Dennis, Stoltze, Lars, Calhoun, Michael E, Jäggi, Fabienne, Wolburg, Hartwig, Gengler, Simon, Haass, Christian, Ghetti, Bernardino, Czech, Christian, Hölscher, Christian, Mathews, Paul M, Jucker, Mathias
Format: Article
Language:English
Subjects:
ageing
Alzheimer
amyloid
microglia transgenic mouse model
Scientific Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron‐specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6–8 weeks and the ratio of human amyloid (A)β42 to Aβ40 is 1.5 and 5 in pre‐depositing and amyloid‐depositing mice, respectively. Consistent with this ratio, extensive congophilic parenchymal amyloid but minimal amyloid angiopathy is observed. Amyloid‐associated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau‐positive neuritic structures and robust gliosis, with neocortical microglia number increasing threefold from 1 to 8 months of age. Global neocortical neuron loss is not apparent up to 8 months of age, but local neuron loss in the dentate gyrus is observed. Because of the early onset of amyloid lesions, the defined genetic background of the model and the facile breeding characteristics, APPPS1 mice are well suited for studying therapeutic strategies and the pathomechanism of amyloidosis by cross‐breeding to other genetically engineered mouse models.
ISSN:1469-221X
1469-3178
DOI:10.1038/sj.embor.7400784